Hong Kong-listed Akeso, Inc. (HKEX: 9926) announced on June 12, 2026 that China's National Medical Products Administration (NMPA) has approved gumokimab (AK111), the company's internally-developed anti-IL-17 IgG1 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis. The approval was supported by the registrational Phase III AK111-301 study, which enrolled Chinese patients at Huashan Hospital, Fudan University under principal investigator Prof. Xu Jinhua, and three supportive studies. A supplemental New Drug Application (sNDA) for gumokimab in active ankylosing spondylitis has already been accepted for review by the Center for Drug Evaluation (CDE) of the NMPA. This is the second Akeso autoimmune drug approved this year — the company already markets ebdarokimab for plaque psoriasis — and a meaningful addition to China's growing bench of domestically-discovered IL-17 pathway inhibitors.
For international patients, the practical story is that a Chinese-discovered, China-domestically-trialed IL-17 monoclonal antibody is now commercially available in China, with a Phase III data set that holds up against (and on some metrics beats) the Western reference drugs in the class, and a dosing schedule that requires fewer injections per year. For patients from countries where IL-17 inhibitors are not yet approved, not reimbursed, or priced out of reach, the gumokimab approval adds a new option to the inbound medical tourism discussion.
Plaque psoriasis is the most common form of psoriasis — the chronic, immune-mediated skin disease that produces red, scaly, well-demarcated plaques typically on the elbows, knees, scalp, and lower back. It affects roughly 125 million people worldwide, with the highest reported prevalence in northern Europe and North America but a substantial and under-counted burden in China, where Akeso estimates the patient population at approximately 6.7 million people. The disease is not life-threatening, but it is life-altering: visible plaques, chronic itching and pain, sleep disruption, social stigma, and a meaningfully elevated risk of depression, anxiety, and cardiovascular comorbidity. Severe psoriasis is associated with a 5-year reduction in life expectancy, mostly driven by that cardiovascular risk.
The standard therapeutic ladder starts with topical steroids and vitamin D analogues, escalates to phototherapy and oral systemics (methotrexate, cyclosporine, acitretin), and lands in biologic therapy for the 20 to 30 percent of patients who have moderate-to-severe disease that does not respond adequately to the first two rungs. The biologic era for psoriasis opened with the TNF inhibitors (etanercept, infliximab, adalimumab) in the mid-2000s, accelerated with the IL-12/23 inhibitor ustekinumab in 2009, and transformed with the IL-17 inhibitors (secukinumab, ixekizumab, brodalumab) starting in 2015. The IL-17 inhibitors, in particular, produced the first sustained near-complete skin clearance in a meaningful fraction of patients — PASI 100, or "completely clear skin," in 30 to 40 percent of patients on the best-in-class molecules — and the IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) have since matched or slightly exceeded that benchmark with less frequent dosing.
Gumokimab is a fully human IgG1 monoclonal antibody that binds IL-17A, the same target as secukinumab (Cosentyx, Novartis) and ixekizumab (Taltz, Eli Lilly). The IL-17 pathway is a cytokine cascade that sits downstream of the IL-23 signal: Th17 cells produce IL-17, IL-17 acts on keratinocytes and other skin-resident cells, and the result is the abnormal proliferation, neutrophil recruitment, and inflammation that produce psoriatic plaques. Blocking IL-17A disrupts this cascade at a point that, in head-to-head trial data, produces faster and deeper skin clearance than the older TNF inhibitors — typically visible improvement at 2 to 4 weeks and maximal clearance at 12 to 16 weeks.
The practical differentiators among IL-17 inhibitors, in 2026, are dosing convenience, durability of response, and the side-effect profile. Secukinumab is dosed every 4 weeks after a monthly loading phase. Ixekizumab is dosed every 2 weeks for the first 12 weeks, then every 4 weeks. Brodalumab (an IL-17 receptor blocker, not strictly an anti-IL-17A) is dosed every 2 weeks for the first 3 doses, then every 2 weeks. Gumokimab, per the AK111-301 protocol, uses a subcutaneous schedule of 17 injections per year including the loading phase — roughly half the annual injection burden of other IL-17 inhibitors, per Akeso's own positioning claim. That is a clinically and operationally meaningful difference for a patient on indefinite biologic therapy.
The registrational Phase III AK111-301 study enrolled Chinese adult patients with moderate-to-severe plaque psoriasis, defined as PASI (Psoriasis Area and Severity Index) score ≥12, body surface area involvement ≥10 percent, and a Physician's Global Assessment (PGA) score of 3 or higher. The trial design was a randomized, double-blind, placebo-controlled evaluation of gumokimab administered subcutaneously at the studied dose, with a primary endpoint of PASI 75 response (at least 75 percent reduction in PASI score from baseline) at Week 12, and key secondary endpoints including PASI 90, PASI 100, and durability of response through Week 52. Three supportive studies provided additional safety and efficacy data across a broader population and earlier lines of therapy.
The reported efficacy data, drawn from the Akeso press release and the AK111-301 topline readout, are unusually clean for a biologic in this class. At Week 12:
Durability of response is the more important question for a chronic disease. The Week 52 data showed:
These durability numbers are the ones that matter for real-world use. A biologic that produces 95 percent PASI 75 at Week 12 is impressive; a biologic that holds 100 percent PASI 75 and 68.9 percent PASI 100 at one year is the kind of profile that justifies indefinite therapy.
The reported safety profile, as summarized in the Akeso press materials, shows incidences of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and infections/infestations that Akeso describes as "numerically among the lowest rates" reported in registrational trials of IL-17 inhibitors. The class-wide safety caveats still apply: IL-17 inhibition is associated with a modestly increased risk of mucocutaneous candidiasis (oral, genital, or skin yeast infections), and there is a small absolute increase in the risk of inflammatory bowel disease (Crohn's, ulcerative colitis) compared to the general population. Patients with a personal or family history of IBD are typically steered away from IL-17 inhibitors and toward IL-23 inhibitors. The full AK111-301 safety dataset — including infection rates, Candida events, IBD cases, malignancy rates, and immunogenicity — has not yet been published in a peer-reviewed journal as of mid-June 2026, and the peer-reviewed paper will be the document international regulators and prescribing dermatologists will want to see.
Akeso's claim is a competitive positioning claim, not a head-to-head trial result. AK111-301 was a placebo-controlled Phase III in Chinese patients; it was not designed as a head-to-head comparison against secukinumab or ixekizumab, and the comparison Akeso is drawing is between AK111-301 and the historical registrational trials of those reference drugs. That kind of cross-trial comparison is informative but not definitive — patient populations, disease severity at baseline, prior biologic exposure, and outcome assessment timing can differ across trials. The right way to validate the gumokimab numbers is a head-to-head Phase III against secukinumab or ixekizumab, which Akeso has not announced. For now, the gumokimab profile is "looks competitive, possibly best-in-class on PASI 100, awaiting peer review and direct comparison."
The gumokimab approval is the second dermatology / autoimmune win for Akeso this year. The company already markets ebdarokimab, an IL-12/23 inhibitor (same target class as ustekinumab) for plaque psoriasis, and now has two internally-discovered, internally-approved biologics in the same indication. That is a meaningful portfolio play — dermatologists can choose between two Akeso drugs with complementary mechanisms for different patient profiles — and it puts Akeso in the same conversation as the larger global IL-17 / IL-23 players (Novartis, Eli Lilly, AbbVie, Janssen) at least in the Chinese market.
Beyond psoriasis, the company has a broader autoimmune and inflammation pipeline:
Akeso is increasingly positioning itself as a Chinese equivalent of the global specialty-biologic players — not just an oncology bispecific shop (its traditional identity) but a broader immunology company. The gumokimab approval is the second domino in that repositioning, and the ankylosing spondylitis sNDA is the third domino waiting to fall. The first autoimmune disease where Akeso has a Phase III win beyond psoriasis will be the test of whether the immunology bet pays off at scale.
IL-17 inhibitors are not just psoriasis drugs. Secukinumab and ixekizumab are both approved for ankylosing spondylitis (AS, also called radiographic axial spondyloarthritis) and for psoriatic arthritis, and the IL-17 class has also shown activity in non-radiographic axial spondyloarthritis, hidradenitis suppurativa, and uveitis. The biology is consistent: IL-17 is a central driver of inflammation in the enthesial and axial skeleton as well as in the skin, and the same antibody that clears psoriatic plaques will often quiet the enthesitis and axial inflammation of spondyloarthritis. Akeso's sNDA for active ankylosing spondylitis, which has been accepted for review by the NMPA's Center for Drug Evaluation, is the natural next indication and would roughly double the addressable patient population for the drug within China.
For international patients, the ankylosing spondylitis angle matters because ankylosing spondylitis is a disease of young adults — typical onset is between 20 and 40 years of age — and a treatment that can quiet the disease without the long-term toxicity of chronic NSAIDs or TNF inhibitors is a significant quality-of-life intervention. China has a large young-adult AS population, the disease is often diagnosed late, and biologic access outside the major cities has historically been limited. A domestically-discovered, domestically-priced IL-17 inhibitor with NMPA approval for AS is a meaningful access expansion.
For an IL-17 monoclonal antibody with established safety and efficacy in skin and joint disease, the standard indication expansion playbook includes psoriatic arthritis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa. Akeso has not announced any of these as planned sNDAs as of June 2026, but the most clinically validated of the three — psoriatic arthritis — is the natural third domino. The relevant Western comparators are secukinumab and ixekizumab, both of which carry psoriatic arthritis labels in addition to their psoriasis and AS labels. Whether Akeso chooses to pursue the full Western label set in China, and whether it eventually seeks FDA / EMA approval for any of these indications outside China, are open questions for 2027 and beyond.
AK111-301 was led at Huashan Hospital, Fudan University in Shanghai, under the principal investigator Prof. Xu Jinhua (徐金华), who is the senior dermatologist running the trial program at Huashan's Department of Dermatology. Huashan is one of the top-ranked dermatology departments in China, with a long history of clinical-trial leadership in psoriasis, atopic dermatitis, and autoimmune skin disease. The hospital is part of the Fudan-affiliated Shanghai cluster, which also includes Zhongshan Hospital, Fudan University Shanghai Cancer Center, and the Eye and ENT Hospital of Fudan University — collectively one of the most concentrated academic-medicine ecosystems in the country.
For international patients considering whether to access gumokimab or another Akeso autoimmune drug in China, the relevant practical details about Huashan are:
Akeso has not, in the June 12 press materials, disclosed a list price for gumokimab in China. The closest reference points are the existing Akeso dermatology biologic ebdarokimab and the Western reference drugs in the IL-17 class. Secukinumab (Cosentyx) lists in the United States at roughly $5,000 to $7,000 per month at the maintenance dose, with annual list prices north of $70,000 and net prices (after rebates) in the $40,000 to $55,000 range. Ixekizumab (Taltz) is in the same bracket. Chinese-domestic pricing for a domestically-discovered IL-17 inhibitor that has just received NMPA approval, in the period before national reimbursement, is typically in the 20,000 to 60,000 yuan per year range (US$2,800 to US$8,500), reflecting the lower price benchmark that has become standard for Chinese specialty biologics. Once gumokimab is included in the national reimbursement drug list (NRDL), the price typically drops to 5,000 to 15,000 yuan per year (US$700 to US$2,100), with patient out-of-pocket determined by the standard reimbursement tier.
For the international patient calculus, the relevant question is what an out-of-pocket foreign patient at a top Chinese hospital would pay for a year of gumokimab. The most realistic estimate, based on the pricing pattern of recently-approved Chinese specialty biologics, is:
For a patient considering gumokimab access in China, the practical options in mid-2026 are:
For the global IL-17 inhibitor market, the gumokimab approval is a second-source Chinese option in a market that, until the 2026 NMPA action, was dominated by secukinumab and ixekizumab in the imported-drug channel, and by domestically-developed molecules like netakimab and the various Chinese-license IL-17 biosimilars. The gumokimab Phase III data — particularly the 47.7 percent PASI 100 at Week 12 and the 68.9 percent PASI 100 at Week 52 — put pressure on the reference drugs to either publish their own durability data more aggressively or to compete on price. For Chinese patients with moderate-to-severe plaque psoriasis, the result is more choice, and over the next 12 to 24 months, more pricing competition.
For the broader autoimmune-and-inflammation pipeline at Akeso, the gumokimab win is also a credibility marker. The company can now claim two internally-discovered, internally-approved biologics for the same indication, with at least one more in late-stage development (manfidokimab, in atopic dermatitis and type 2 inflammation) and a first-in-class bispecific (AK139, IL-4Rα/ST2) in earlier development. That pipeline depth is what the larger global specialty-biologic players bring to the autoimmune market, and Akeso is now one of the few Chinese biotechs with the internal R&D and clinical-trial infrastructure to compete in that conversation.
Akeso's gumokimab is the second major NMPA autoimmune approval of 2026 from a Chinese-discovered molecule, following the Antengene ATG-201 CD19 × CD3 bispecific IND clearance for B-cell autoimmune disease on June 10, 2026 (covered in our prior piece on the Antengene trial). The two approvals, two days apart, are not a coincidence: they reflect a deliberate pivot by a generation of Chinese biotechs that built their first commercial products in oncology (the PD-1 / PD-L1 / bispecific era of 2018 to 2024) and are now extending those same biologic-engineering capabilities into autoimmune and inflammatory disease. The result, for international patients, is that China is becoming a real source of next-generation autoimmune therapeutics — not just the established TNF, IL-6, and IL-17 monoclonals, but the next wave of bispecifics, dual-targets, and biologics for B-cell driven disease.
If you or a family member has moderate-to-severe plaque psoriasis, psoriatic arthritis, or ankylosing spondylitis, and you are considering either inbound travel to China for commercial gumokimab access or enrollment in a follow-on Akeso clinical trial, the practical workflow is:
For a moderate-to-severe plaque psoriasis prescription, the receiving hospital will want to see the diagnostic confirmation (typically a dermatologist's clinical assessment, sometimes a biopsy), the current PASI or BSA measurement, and the prior treatment history — what topicals, what phototherapy, what oral systemics, what biologics, with dates and outcomes. For active ankylosing spondylitis, you will need the ASAS classification criteria workup, the BASDAI / BASFI scores, and the imaging evidence (X-ray or MRI of the sacroiliac joints).
Before committing to travel, request a written cost estimate from the receiving hospital's international patient office. The estimate should include the drug cost (per dose, with the projected annual dose count), the hospital fees for the induction and follow-up visits, the lab monitoring schedule, and any imaging required. Confirm the drug pricing assumption (pre-NRDL or post-NRDL) and the out-of-pocket total.
For plaque psoriasis, the initial visit typically involves a one- to two-week stay in the destination city for induction dosing (the loading phase of gumokimab requires more frequent doses in the first 2 to 4 weeks), with follow-up visits every 4 to 12 weeks for the first year. Most major Chinese academic dermatology centers can coordinate a multi-visit plan that minimizes total on-site time, with the loading phase in China and the maintenance phase managed remotely with a local dermatologist at home for routine monitoring and the China hospital for periodic in-person check-ins.
All of the major Chinese academic dermatology centers have English-speaking dermatologists and dedicated international patient coordinators. Written medical-record translation is the patient's responsibility, and most of the top centers can recommend a translation service. Bring a translated copy of your diagnostic workup, prior treatment history, and any relevant lab results to the first appointment.
Gumokimab is administered as a subcutaneous injection. After the first dose under medical supervision, most patients can self-inject at home with proper training. The Chinese hospital team will train you or a family member on injection technique, storage, and side-effect monitoring. For the maintenance phase, the drug can be shipped from the hospital pharmacy to your home or accommodation in China, or carried back to your home country in temperature-controlled packaging for the next dose window.
If you intend to continue gumokimab in your home country after the initial course in China, coordinate with a local dermatologist who is willing to manage the maintenance phase. Not all dermatologists outside China will be willing to manage a Chinese-domestic biologic, so confirm the plan in advance. For the loading phase, the Chinese hospital is the prescribing physician. For the maintenance phase, the local dermatologist assumes responsibility.
The gumokimab approval is a substantive clinical and commercial event, but the longer-term story is still being written. The next 12 months will be telling. Watch for:
For international patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, or ankylosing spondylitis, the bottom line is that a new, well-dosed, competitively priced IL-17 monoclonal antibody is now commercially available in China, with a Phase III data set that holds its own against the Western reference drugs in the class. For patients in countries where gumokimab is not yet approved or not yet reimbursed, the inbound path to China is the realistic near-term option. For the longer term, the question is whether Akeso chooses to take gumokimab — or any of its broader autoimmune portfolio — through FDA / EMA approval on its own, or whether it follows the China-discovered-globally-licensed template that the Antengene / UCB and BeiGene / AstraZeneca arrangements have used.
Considering gumokimab access or another biologic in China?
Our team can help with pre-screening, medical-records translation, hospital coordination, and travel logistics for biologic therapy at Huashan, Shanghai Skin Disease Hospital, PKUPH, and other top Chinese academic centers.
Get a Free Pre-Screening Assessment